MarketTeneligliptin
Company Profile

Teneligliptin

Teneligliptin is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".

Creation
It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan. ==Licensing and use==
Licensing and use
Japan/Korea/India/Argentina It is approved for use in Japan, Argentina, Korea and India. ==Pharmacology==
Pharmacology
Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme. Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients. == References ==
tickerdossier.comtickerdossier.substack.com